[{"address1": "11025 North Torrey Pines Road", "address2": "Suite 140", "city": "La Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "858 795 4220", "website": "https://inhibrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.", "fullTimeEmployees": 156, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark Paul Lappe", "age": 57, "title": "Founder, CEO & Chairman", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 1130194, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly Devine Deck B.S., CPA, M.S.", "age": 44, "title": "Executive VP, CFO & Treasurer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 2190588, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David J. Matly M.B.A.", "age": 38, "title": "President", "yearBorn": 1986, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Bonne  Adams M.B.A.", "age": 47, "title": "Vice President of Operations", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashraf  Amanullah Ph.D.", "age": 56, "title": "Executive VP & Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Carlos  Bais Ph.D.", "title": "EVP & Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leah  Pollema J.D.", "title": "VP, General Counsel & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Josep  Garcia Ph.D.", "title": "Executive VP & Chief Clinical Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 6, "overallRisk": 8, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 78.51, "open": 77.99, "dayLow": 75.13, "dayHigh": 83.95, "regularMarketPreviousClose": 78.51, "regularMarketOpen": 77.99, "regularMarketDayLow": 75.13, "regularMarketDayHigh": 83.88, "payoutRatio": 0.0, "forwardPE": -7.4034457, "volume": 480194, "regularMarketVolume": 480194, "averageVolume": 298642, "averageVolume10days": 1231200, "averageDailyVolume10Day": 1231200, "bid": 59.19, "ask": 97.62, "bidSize": 2, "askSize": 2, "marketCap": 1182879488, "fiftyTwoWeekLow": 10.805, "fiftyTwoWeekHigh": 83.95, "allTimeHigh": 83.95, "allTimeLow": 10.8, "priceToSalesTrailing12Months": 844.91394, "fiftyDayAverage": 35.4902, "twoHundredDayAverage": 20.35015, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1103101440, "profitMargins": 0.0, "floatShares": 8158479, "sharesOutstanding": 14485421, "sharesShort": 532661, "sharesShortPriorMonth": 721500, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0368, "heldPercentInsiders": 0.27174, "heldPercentInstitutions": 0.63120997, "shortRatio": 3.44, "shortPercentOfFloat": 0.0507, "impliedSharesOutstanding": 14485421, "bookValue": 4.736, "priceToBook": 17.2424, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -163694000, "trailingEps": -16.57, "forwardEps": -11.03, "enterpriseToRevenue": 787.93, "enterpriseToEbitda": -11.47, "52WeekChange": 4.2514467, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 81.66, "recommendationKey": "none", "totalCash": 186567008, "totalCashPerShare": 12.88, "ebitda": -96169000, "totalDebt": 106789000, "quickRatio": 4.816, "currentRatio": 4.981, "totalRevenue": 1400000, "debtToEquity": 155.762, "revenuePerShare": 0.09, "returnOnAssets": -0.26288, "returnOnEquity": -1.13706, "grossProfits": -171768992, "freeCashflow": -42974000, "operatingCashflow": -139848992, "revenueGrowth": 12.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -21.068459, "financialCurrency": "USD", "symbol": "INBX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Inhibrx Biosciences, Inc.", "regularMarketChangePercent": 4.01223, "regularMarketPrice": 81.66, "longName": "Inhibrx Biosciences, Inc.", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 298642, "fiftyTwoWeekLowChange": 70.855, "fiftyTwoWeekLowChangePercent": 6.5576124, "fiftyTwoWeekRange": "10.805 - 83.95", "fiftyTwoWeekHighChange": -2.2899933, "fiftyTwoWeekHighChangePercent": -0.027278062, "fiftyTwoWeekChangePercent": 425.14468, "earningsTimestamp": 1763150400, "earningsTimestampStart": 1763150400, "earningsTimestampEnd": 1763150400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -16.57, "epsForward": -11.03, "epsCurrentYear": -8.12, "priceEpsCurrentYear": -10.056651, "fiftyDayAverageChange": 46.169804, "fiftyDayAverageChangePercent": 1.300917, "twoHundredDayAverageChange": 61.309853, "twoHundredDayAverageChangePercent": 3.012747, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-19", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1716989400000, "postMarketChangePercent": 0.17144181, "postMarketPrice": 81.8, "postMarketChange": 0.13999939, "regularMarketChange": 3.15, "regularMarketDayRange": "75.13 - 83.88", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1761949505, "regularMarketTime": 1761940801, "exchange": "NMS", "messageBoardId": "finmb_1873020488", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Inhibrx Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]